Journal of Clinical Investigation · 2017 · 110 citations · 65 references
Life SciencesImmunologyMolecular GeneticsAutoimmunityInflammationInnate ImmunityInflammatory SignalingInnate Immune ResponseInnate Immune Signaling PathwaysInterferon ResponsesSystemic Lupus ErythematosusToll-like ReceptorsInterferon Pathway GenesInterferon Pathway GeneticsInterferon Regulatory Factor ActivationInterferon-mediated PathologyMacrophage Interferon ResponsesProinflammatory MediatorsSystemic Lupus Erythematosus AssociationsType I Interferon Pathways
Genetic variations in the ITGAM gene (encoding CD11b) strongly associate with risk for systemic lupus erythematosus (SLE). Here we have shown that 3 nonsynonymous ITGAM variants that produce defective CD11b associate with elevated levels of type I interferon (IFN-I) in lupus, suggesting a direct link between reduced CD11b activity and the chronically increased inflammatory status in patients. Treatment with the small-molecule CD11b agonist LA1 led to partial integrin activation, reduced IFN-I responses in WT but not CD11b-deficient mice, and protected lupus-prone MRL/Lpr mice from end-organ injury. CD11b activation reduced TLR-dependent proinflammatory signaling in leukocytes and suppressed IFN-I signaling via an AKT/FOXO3/IFN regulatory factor 3/7 pathway. TLR-stimulated macrophages from CD11B SNP carriers showed increased basal expression of IFN regulatory factor 7 (IRF7) and IFN-β, as well as increased nuclear exclusion of FOXO3, which was suppressed by LA1-dependent activation of CD11b. This suggests that pharmacologic activation of CD11b could be a potential mechanism for developing SLE therapeutics.
65
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Kenya Honda, Hideyuki Yanai, Hideo Negishi et al. · Nature · 2005 · 2.2K citations
John B. Harley, Marta E. Alarcón‐Riquelme, Lindsey A. Criswell et al. · Nature Genetics · 2008 · 1.3K citations